PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Holdings Lifted by Robocap Asset Management Ltd

Robocap Asset Management Ltd grew its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 21.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 111,004 shares of the company's stock after purchasing an additional 19,933 shares during the quarter. PROCEPT BioRobotics comprises approximately 4.8% of Robocap Asset Management Ltd's portfolio, making the stock its 8th biggest holding. Robocap Asset Management Ltd owned 0.20% of PROCEPT BioRobotics worth $6,467,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Thematics Asset Management bought a new position in PROCEPT BioRobotics during the fourth quarter worth about $46,000. Signaturefd LLC boosted its position in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares during the period. WINTON GROUP Ltd bought a new position in PROCEPT BioRobotics during the fourth quarter worth about $207,000. Freestone Grove Partners LP bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $207,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $213,000. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Trading Up 0.9%

Shares of PRCT traded up $0.55 during mid-day trading on Wednesday, reaching $58.46. The company's stock had a trading volume of 841,546 shares, compared to its average volume of 845,775. The stock has a market cap of $3.23 billion, a PE ratio of -34.39 and a beta of 1.07. The company has a current ratio of 8.95, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13. PROCEPT BioRobotics Corporation has a 52 week low of $47.04 and a 52 week high of $103.81. The company's fifty day moving average price is $58.14 and its two-hundred day moving average price is $63.23.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. The business's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.51) EPS. On average, analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the transaction, the director directly owned 14,363 shares of the company's stock, valued at $883,180.87. The trade was a 63.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 100,000 shares of company stock valued at $6,271,250. Insiders own 6.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PRCT. Stephens began coverage on shares of PROCEPT BioRobotics in a research report on Wednesday. They issued an "overweight" rating and a $70.00 price objective for the company. Bank of America cut their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Truist Financial cut their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Oppenheimer began coverage on shares of PROCEPT BioRobotics in a research report on Monday. They issued a "market perform" rating for the company. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $87.50.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).